Esketamine - Wikipedia
Esketamine is the active enantiomer of ketamine in terms of NMDA receptor antagonism and is more potent than racemic ketamine. [14] It is specifically used as a therapy for treatment-resistant depression (TRD) and for major depressive disorder (MDD) with …
Esketamine for Treatment-Resistant Depression - Johns Hopkins Medicine
There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours.
SPRAVATO® (esketamine) approved in the U.S. as the first and …
5 days ago · SPRAVATO ® (esketamine) CIII nasal spray is approved by the U.S. Food and Drug Administration alone or in conjunction with an oral antidepressant for adults with MDD when they have inadequate response to at least two oral antidepressants (TRD) and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or ...
FDA Expands Approval of Intranasal Esketamine Therapy (Spravato)
5 days ago · In a significant step forward for mental health care, the U.S. Food and Drug Administration (FDA) has expanded its approval of Spravato (esketamine) nasal spray. Initially approved in 2019 for treatment-resistant depression, Spravato is now cleared for use as a standalone treatment for major depressive disorder (MDD).
FDA Approves Esketamine as First Monotherapy for Treatment …
6 days ago · The US Food and Drug Administration (FDA) approved esketamine (SPRAVATO) CIII nasal spray as the first monotherapy for adults with treatment-resistant depression (TRD), announced by Johnson & Johnson on January 21, 2025. 1. The approval of this supplemental New Drug Application (sNDA) was based on phase 4 randomized, double-blind, multicenter, …
Esketamine: Indications, Side Effects, Warnings - Drugs.com
Apr 22, 2024 · Easy-to-read patient leaflet for Esketamine. Includes indications, proper use, special instructions, precautions, and possible side effects. Skip to main content
Esketamine (nasal route) - Mayo Clinic
Sep 1, 2024 · Esketamine nasal spray is used together with an antidepressant taken by mouth, to treat patients with depression who have previously received at least 2 antidepressant treatments that did not work well (treatment-resistant depression).
Esketamine for treatment‑resistant depression: A review of clinical ...
Esketamine has been shown to be effective in decreasing the severity of short-term depressive symptoms, but questions about its medium- and long-term action, as well as its tolerability profile, remain to be elucidated as novel clinical studies explore its pharmaco-clinical properties.
Esketamine (Spravato) | NAMI
Esketamine is an intranasal medication that works in the brain. Esketamine is approved for the treatment of treatment-resistant depression (TRD) in conjunction with an oral antidepressant. It is also FDA approved for major depressive disorder (MDD) with suicidal thoughts and behavior.
Esketamine Monograph for Professionals - Drugs.com
Jun 10, 2024 · Esketamine is the S-enantiomer of racemic ketamine, a derivative of phencyclidine (PCP). The drug is a nonselective, noncompetitive antagonist of the NMDA receptor (an inotropic glutamate receptor). Esketamine has a higher affinity for the NMDA receptor than the R-enantiomer of racemic ketamine.